{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:42:51Z","timestamp":1791272571638,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd011567","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,9,12]],"date-time":"2016-09-12T00:00:00Z","timestamp":1473638400000}}],"reference-count":193,"publisher":"Wiley","issue":"9","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011567.pub2","type":"journal-article","created":{"date-parts":[[2016,9,12]],"date-time":"2016-09-12T19:51:14Z","timestamp":1473709874000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Antidepressants and benzodiazepines for panic disorder in adults"],"prefix":"10.1002","volume":"2016","author":[{"given":"Irene","family":"Bighelli","sequence":"first","affiliation":[{"name":"University of Verona; Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry; Verona Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlotta","family":"Trespidi","sequence":"additional","affiliation":[{"name":"University of Verona; Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry; Verona Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariasole","family":"Castellazzi","sequence":"additional","affiliation":[{"name":"University of Verona; Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry; Verona Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cipriani","sequence":"additional","affiliation":[{"name":"University of Oxford; Department of Psychiatry; Warneford Hospital Oxford UK OX3 7JX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshi A","family":"Furukawa","sequence":"additional","affiliation":[{"name":"Kyoto University Graduate School of Medicine\/School of Public Health; Department of Health Promotion and Human Behavior; Yoshida Konoe-cho, Sakyo-ku, Kyoto Japan 606-8501"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Girlanda","sequence":"additional","affiliation":[{"name":"University of Verona; Department of Public Health and Community Medicine, Section of Psychiatry; Policlinico \"G.B.Rossi\" Piazzale L.A. Scuro, 10 Verona Italy 37134"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Guaiana","sequence":"additional","affiliation":[{"name":"Western University; Department of Psychiatry; Saint Thomas Elgin General Hospital 189 Elm Street St Thomas ON Canada N5R 5C4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Koesters","sequence":"additional","affiliation":[{"name":"Ulm University; Department of Psychiatry II; Ludwig-Heilmeyer-Str. 2 Guenzburg Germany D-89312"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Barbui","sequence":"additional","affiliation":[{"name":"University of Verona; Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry; Verona Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,9,12]]},"reference":[{"issue":"6","key":"10.1002\/14651858.CD011567.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/(SICI)1099-1077(199908)14:6<429::AID-HUP108>3.0.CO;2-3","article-title":"Panic disorder. A long-term treatment study: fluoxetine vs imipramine","volume":"14","author":"Amore","year":"1999","journal-title":"Human Psychopharmacology: Clinical and Experimental"},{"issue":"6","key":"10.1002\/14651858.CD011567.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/(SICI)1099-1077(199908)14:6<435::AID-HUP109>3.0.CO;2-B","article-title":"Short-term and long-term evaluation of selective serotonin reuptake inhibitors in the treatment of panic disorder: fluoxetine vs citalopram","volume":"14","author":"Amore","year":"1999","journal-title":"Human Psychopharmacology: Clinical and Experimental"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011567.pub2-BIB0003|cit3","first-page":"S77","article-title":"Reversible monoamine oxidase-A inhibitors in panic disorder","volume":"16","author":"Bakish","year":"1993","journal-title":"Clinical Neuropharmacology"},{"issue":"1 Pt B","key":"10.1002\/14651858.CD011567.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00002826-199202001-00115","article-title":"Brofaromine and clomipramine in panic disorder: a double-blind study","volume":"15","author":"Saxena","year":"1992","journal-title":"Clinical Neuropharmacology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD011567.pub2-BIB0005|cit5","first-page":"S363","article-title":"Sertraline versus paroxetine in the treatment of panic disorder: a multinational randomized double-blind 15 week study","volume":"12","author":"Bandelow","year":"2002","journal-title":"European Neuropsychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD011567.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4088\/JCP.v65n0317","article-title":"Sertraline versus paroxetine in the treatment of panic disorder: an acute, double-blind noninferiority comparison","volume":"65","author":"Bandelow","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD011567.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/anxi.3070010608","article-title":"Double-blind pilot trial of desipramine versus fluoxetine in panic patients","volume":"1","author":"Bystritsky","journal-title":"Anxiety"},{"issue":"5","key":"10.1002\/14651858.CD011567.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1600-0447.1990.tb01401.x","article-title":"Drug treatment of panic disorder: early response to treatment as a predictor of final outcome","volume":"82","author":"Albus","year":"1990","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"2","key":"10.1002\/14651858.CD011567.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/BF02189978","article-title":"Consistencies and discrepancies in self- and observer-rated anxiety scales. A comparison between the self- and observer-rated Marks-Sheehan scales","volume":"240","author":"Albus","year":"1990","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"issue":"3","key":"10.1002\/14651858.CD011567.pub2-BIB0010|cit10","first-page":"145","article-title":"Panic disorder: a five-year follow-up study in 52 patients","volume":"11","author":"Andersch","year":"1997","journal-title":"European Journal of Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD011567.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.eurpsy.2003.03.007","article-title":"A 15-year follow-up study of patients with panic disorder","volume":"18","author":"Andersch","year":"2003","journal-title":"European Psychiatry"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1600-0447.1991.tb03097.x","article-title":"Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder. A Scandinavian multicenter study","volume":"365","author":"Andersch","year":"1991","journal-title":"Acta Psychiatrica Scandinavica. Supplementum"},{"issue":"1","key":"10.1002\/14651858.CD011567.pub2-BIB0013|cit13","first-page":"1","article-title":"Pharmacologic treatment of panic disorders: Comparative report on the efficacy and safety of alprazolam and imipramine in a controlled study","volume":"14","author":"Berlanga","year":"1991","journal-title":"Salud Mental"},{"issue":"3","key":"10.1002\/14651858.CD011567.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/BF02190758","article-title":"Chronology of panic and avoidance, age of onset in panic disorder, and prediction of treatment response. A report from the Cross-National Collaborative Panic Study","volume":"240","author":"Buller","year":"1991","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"issue":"1","key":"10.1002\/14651858.CD011567.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0924-977X(94)90314-X","article-title":"Adverse effects associated with the short-term treatment of panic disorder with imipramine, alprazolam or placebo","volume":"4","author":"Cassano","year":"1994","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1192\/bjp.160.2.191","article-title":"Drug treatment of panic disorder: Comparative efficacy of alprazolam, imipramine, and placebo","volume":"160","author":"Cross National Collaborative Panic Study Second Phase Investigators","year":"1992","journal-title":"British Journal of Psychiatry"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011567.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0022-3956(93)90023-U","article-title":"Maintenance drug therapy of panic disorder","volume":"27","author":"Curtis","year":"1993","journal-title":"Journal of Psychiatry Research"},{"issue":"2","key":"10.1002\/14651858.CD011567.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/0010-440X(91)90003-U","article-title":"The sequence of improvement of the symptoms encountered in patients with panic disorder","volume":"32","author":"Deltito","year":"1991","journal-title":"Comprehensive Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD011567.pub2-BIB0019|cit19","first-page":"121","article-title":"Patients with panic disorder unaccompanied by depression improve with alprazolam and imipramine treatment","volume":"52","author":"Deltito","year":"1991","journal-title":"Journal of Clinical Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD011567.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1521\/pedi.1988.2.4.303","article-title":"Personality disorders in panic patients: Response to termination of antipanic medication","volume":"2","author":"Green","year":"1988","journal-title":"Journal of Personality Disorders"},{"issue":"4","key":"10.1002\/14651858.CD011567.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1192\/bjp.167.4.487","article-title":"Long-term follow-up after a drug trial for panic disorder","volume":"167","author":"Katschnig","year":"1995","journal-title":"British Journal of Psychiatry"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011567.pub2-BIB0023|cit22","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0022-3956(90)90033-M","article-title":"Depression and panic anxiety: the effect of depressive co-morbidity on response to drug treatment of patients with panic disorder and agoraphobia","volume":"24","author":"Klerman","year":"1990","journal-title":"Journal of Psychiatric Research"},{"issue":"1","key":"10.1002\/14651858.CD011567.pub2-BIB0022|cit23","first-page":"59","article-title":"The design and conduct of the Upjohn Cross-National Collaborative Panic Study","volume":"22","author":"Klerman","year":"1986","journal-title":"Psychopharmacology Bulletin"},{"issue":"17","key":"10.1002\/14651858.CD011567.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/sim.4780141707","article-title":"A multiple imputation strategy for clinical trials with truncation of patient data","volume":"14","author":"Lavori","year":"1995","journal-title":"Statistics in Medicine"},{"issue":"1-2","key":"10.1002\/14651858.CD011567.pub2-BIB0025|cit25","first-page":"59","article-title":"Comparison of the effect of alprazolam, imipramine and placebo in the treatment of panic disorders in Cali, Colombia","volume":"36","author":"Le\u00f3n","year":"1990","journal-title":"Acta Psiquiatrica y Psicologica de America Latina"},{"issue":"2","key":"10.1002\/14651858.CD011567.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF02189979","article-title":"Self- and observer assessment in anxiolytic drug trials: a comparison of their validity","volume":"240","author":"Maier","year":"1990","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"issue":"3","key":"10.1002\/14651858.CD011567.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/BF02219714","article-title":"Avoidance behaviour: a predictor of the efficacy of pharmacotherapy in panic disorder?","volume":"241","author":"Maier","year":"1991","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"issue":"6","key":"10.1002\/14651858.CD011567.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3928\/0048-5713-19910601-11","article-title":"Agoraphobia in panic disorder: An indicator of the severity of panic disorder or a distinct diagnostic entity?","volume":"21","author":"Maier","year":"1991","journal-title":"Psychiatric Annals"},{"issue":"6","key":"10.1002\/14651858.CD011567.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/0010-440X(91)90035-B","article-title":"The sequence of improvement of the symptoms encountered in patients with panic disorder","volume":"32","author":"Rifkin","year":"1991","journal-title":"Comprehensive Psychiatry"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1600-0447.1991.tb03099.x","article-title":"Characteristics of panic disorder patients responding to placebo","volume":"365","author":"Rosenberg","year":"1991","journal-title":"Acta Psychiatrica Scandinavica Supplementum"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1600-0447.1991.tb03101.x","article-title":"Alprazolam, imipramine and placebo treatment of panic disorder: predicting therapeutic response","volume":"365","author":"Rosenberg","year":"1991","journal-title":"Acta Psychiatrica Scandinavica. Supplementum"},{"issue":"2","key":"10.1002\/14651858.CD011567.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0887-6185(02)00183-4","article-title":"The long-term course of panic disorder--an 11 year follow-up","volume":"17","author":"Swoboda","year":"2003","journal-title":"Journal of Anxiety Disorders"},{"issue":"1","key":"10.1002\/14651858.CD011567.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00004850-198801000-00005","article-title":"Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline","volume":"3","author":"Boer","year":"1988","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/BF02245749","article-title":"Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin","volume":"102","author":"Boer","year":"1990","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD011567.pub2-BIB0035|cit35","first-page":"119","article-title":"Selective monoamine uptake inhibitors and a serotonin antagonist in the treatment of panic disorder","volume":"25","author":"Westenberg","year":"1989","journal-title":"Psychopharmacology Bulletin"},{"issue":"1","key":"10.1002\/14651858.CD011567.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0165-1781(89)90171-6","article-title":"The relationship of panic disorder and its treatment outcome to 24-hour urinary MHPG levels","volume":"30","author":"Garvey","year":"1989","journal-title":"Psychiatry Research"},{"issue":"4","key":"10.1002\/14651858.CD011567.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1177\/026988119300700402","article-title":"Clomipramine, a better reference drug for panic\/agoraphobia. I. Effectiveness comparison with imipramine","volume":"7","author":"Gentil","year":"1993","journal-title":"Journal of Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD011567.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1177\/026988119300700403","article-title":"Clomipramine, a better reference drug for panic\/agoraphobia. II. Psychomotor and cognitive effects","volume":"7","author":"Marcourakis","year":"1993","journal-title":"Journal of Psychopharmacology"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0039|cit39","unstructured":"GSK A double-blind, multicenter, flexible-dose study of paroxetine, alprazolam and placebo in the treatment of panic disorder GSK Clinical Studies Register [http:\/\/www.gsk-clinicalstudyregister.com\/]"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0040|cit40","unstructured":"GSK A double blind, multicenter randomized drug-controlled study to assess the efficacy and tolerance of paroxetine compared with clomipramine in treatment of panic disorder GSK Clinical Studies Register [http:\/\/www.gsk-clinicalstudyregister.com\/]"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/(SICI)1099-1077(199903)14:2<119::AID-HUP77>3.0.CO;2-1","article-title":"Specific effects of benzodiazepines and tricyclic antidepressants in panic disorder: comparisons of clomipramine with alprazolam SR and adinazolam SR","volume":"14","author":"Holland","year":"1999","journal-title":"Human Psychopharmacology Clinical Experimental"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011567.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1007\/PL00014163","article-title":"The efficacy and safety of moclobemide compared to clomipramine in the treatment of panic disorder","volume":"249","author":"Krueger","year":"1999","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0043|cit43","unstructured":"GlaxoSmithKline A double-blind placebo controlled comparative study of paroxetine and clomipramine in the treatment of panic disorder GSK-ClinicalStudy Register (www.gsk-clinicalstudyregister.com)"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1600-0447.1997.tb00388.x","article-title":"A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder","volume":"95","author":"Lecrubier","year":"1997","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1600-0447.1997.tb00389.x","article-title":"Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder","volume":"95","author":"Lecrubier","year":"1997","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/hup.470050209","article-title":"Clinical evaluation of alprazolam in patients with panic disorder; a double-blind comparison with imipramine","volume":"5","author":"Lepola","year":"1990","journal-title":"Human Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD011567.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/08039489850139175","article-title":"Spectral electroencephalogram and clinical follow-up during alprazolam and imipramine treatment in panic disorder","volume":"52","author":"Rimon","year":"1998","journal-title":"Nordic Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD011567.pub2-BIB0048|cit48","first-page":"196","article-title":"Etizolam: a new therapeutic possibility in the treatment of panic disorder","volume":"6","author":"Meco","year":"1989","journal-title":"Advances in Therapy"},{"issue":"1","key":"10.1002\/14651858.CD011567.pub2-BIB0049|cit49","first-page":"135","article-title":"A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia","volume":"32","author":"Bakish","year":"1996","journal-title":"Psychopharmacology Bulletin"},{"issue":"4","key":"10.1002\/14651858.CD011567.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/(SICI)1522-7154(1996)2:4<192::AID-ANXI6>3.0.CO;2-Q","article-title":"Comparison of fluvoxamine, imipramine, and placebo in the treatment of outpatients with panic disorder","volume":"2","author":"Nair","year":"1996","journal-title":"Anxiety"},{"issue":"8","key":"10.1002\/14651858.CD011567.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/0006-3223(89)90287-4","article-title":"The significance of HPA axis disturbance in panic disorder","volume":"25","author":"Coryell","year":"1989","journal-title":"Biological Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD011567.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0306-4530(90)90043-9","article-title":"Reduction in urinary free cortisol during benzodiazepine treatment of panic disorder","volume":"15","author":"Lopez","year":"1990","journal-title":"Psychoneuroendocrinology"},{"issue":"8","key":"10.1002\/14651858.CD011567.pub2-BIB0053|cit53","first-page":"349","article-title":"Diazepam versus alprazolam for the treatment of panic disorder","volume":"57","author":"Noyes","year":"1996","journal-title":"Journal of Clinical Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD011567.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1176\/ajp.148.4.517","article-title":"Controlled discontinuation of benzodiazepine treatment for patients with panic disorder","volume":"148","author":"Noyes","year":"1991","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0055|cit55","unstructured":"Pfizer A randomized, double-blind, multicenter study of sertraline compared with paroxetine In the treatment of panic disorder http:\/\/clinicaltrials.gov\/show\/NCT00677352 2008"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00213-007-0821-0","article-title":"A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder","volume":"194","author":"Pollack","year":"2007","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0057|cit57","unstructured":"Pollack M Whitaker T Mangano R Gao B A comparison of venlafaxine XR and paroxetine in the treatment of outpatients with panic disorder ACNP 2004 Annual Meeting S201 S202"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/da.20218","article-title":"A double-blind study of the efficacy of venlafaxine extended-release, paroxetine and placebo in the treatment of panic disorder","volume":"24","author":"Pollack","year":"2007","journal-title":"Depression and Anxiety"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1590\/S0100-879X2001001000010","article-title":"Mirtazapine versus fluoxetine in the treatment of panic disorder","volume":"34","author":"Ribeiro","year":"2001","journal-title":"Brazilian Journal of Medical and Biological Research"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0924-977X(98)00024-8","article-title":"A double-blind crossover comparison of clomipramine and desipramine in the treatment of panic disorder","volume":"9","author":"Sasson","year":"1999","journal-title":"European Neuropsychopharmacology"},{"issue":"6 Suppl 2","key":"10.1002\/14651858.CD011567.pub2-BIB0062|cit61","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/00004714-199812001-00004","article-title":"Panic disorder: Long-term pharmacotherapy and discontinuation","volume":"18","author":"Rickels","year":"1998","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0061|cit62","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1001\/archpsyc.1993.01820130067010","article-title":"Maintenance drug treatment for panic disorder. II. Short- and long-term outcome after drug taper","volume":"50","author":"Rickels","year":"1993","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/archpsyc.1993.01820130053009","article-title":"Maintenance drug treatment of panic disorder. I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine","volume":"50","author":"Schweizer","year":"1993","journal-title":"Archives of General Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD011567.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2190\/KQEJ-MQJR-VK3D-F3HV","article-title":"Treatment of panic disorder in older adults: a pilot study comparison of alprazolam, imipramine, and placebo","volume":"29","author":"Sheikh","year":"1999","journal-title":"International Journal of Psychiatry in Medicine"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1055\/s-2007-984398","article-title":"Improvement of quality of life in panic disorder with escitalopram, citalopram, or placebo","volume":"40","author":"Bandelow","year":"2007","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0066|cit66","unstructured":"Forest Laboratories Flexible-dose comparison of the safety and efficacy of Lu 26-054 (escitalopram), citalopram and placebo in the treatment of panic disorder Forest Laboratories Clinical Study Register [www.forestclinicaltrials.com]"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.4088\/JCP.v64n1107","article-title":"Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial","volume":"64","author":"Stahl","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD011567.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1176\/ajp.147.4.507","article-title":"Surreptitious drug use by patients in a panic disorder study","volume":"147","author":"Clark","year":"1990","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD011567.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1037\/0022-006X.59.1.184","article-title":"How \"blind\" are double-blind studies?","volume":"59","author":"Margraf","year":"1991","journal-title":"Journal of Consulting and Clinical Psychology"},{"issue":"2","key":"10.1002\/14651858.CD011567.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/00004714-199004000-00006","article-title":"Cardiovascular and symptomatic reduction effects of alprazolam and imipramine in patients with panic disorder: results of a double-blind, placebo-controlled trial","volume":"10","author":"Taylor","year":"1990","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD011567.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0165-1781(89)90215-1","article-title":"Dehydroepiandrosterone-sulfate\/cortisol ratio in panic disorder","volume":"28","author":"Fava","year":"1989","journal-title":"Psychiatry Research"},{"issue":"4","key":"10.1002\/14651858.CD011567.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/00004714-199408000-00008","article-title":"The relationship of alprazolam and clonazepam dose to steady-state concentration in plasma","volume":"14","author":"Labbate","year":"1994","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD011567.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00004714-199308000-00005","article-title":"Long-term outcome after acute treatment with alprazolam or clonazepam for panic disorder","volume":"13","author":"Pollack","year":"1993","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD011567.pub2-BIB0074|cit74","first-page":"16","article-title":"Clonazepam versus alprazolam in the treatment of panic disorder: interim analysis of data from a prospective, double-blind, placebo-controlled trial","volume":"48","author":"Tesar","year":"1987","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD011567.pub2-BIB0075|cit75","first-page":"69","article-title":"Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder","volume":"52","author":"Tesar","year":"1991","journal-title":"Journal of Clinical Psychiatry"},{"issue":"Suppl1","key":"10.1002\/14651858.CD011567.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1007\/PL00014164","article-title":"Moclobemide and fluoxetine for panic disorder","volume":"249","author":"Tiller","year":"1999","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"issue":"3","key":"10.1002\/14651858.CD011567.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0165-0327(89)90009-8","article-title":"Response of panic disorder to fixed doses of alprazolam or imipramine","volume":"17","author":"Uhlenhuth","year":"1989","journal-title":"Journal of Affective Disorders"},{"issue":"1","key":"10.1002\/14651858.CD011567.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0165-0327(94)00070-P","article-title":"Phobic symptoms as predictors of nonresponse to drug therapy in panic disorder patients (a preliminary report)","volume":"33","author":"Slaap","year":"1995","journal-title":"Journal of Affective Disorders"},{"issue":"4","key":"10.1002\/14651858.CD011567.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/00004714-199608000-00005","article-title":"A double-blind comparative study of brofaromine and fluvoxamine in outpatients with panic disorder","volume":"16","author":"Vliet","year":"1996","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD011567.pub2-BIB0080|cit80","first-page":"24","article-title":"Citalopram controls phobic symptoms in patients with panic disorder: randomized controlled trial","volume":"25","author":"Leinonen","year":"2000","journal-title":"Journal of Psychiatry and Neuroscience"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"528","DOI":"10.4088\/JCP.v59n1006","article-title":"A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder","volume":"59","author":"Lepola","year":"1998","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"S221","DOI":"10.1016\/S0924-977X(99)80150-3","article-title":"Weight monitoring during two long-term trials of citalopram","volume":"9 Suppl 5","author":"Wade","year":"1999","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1192\/bjp.170.6.549","article-title":"The effect of citalopram in panic disorder","volume":"170","author":"Wade","year":"1997","journal-title":"British Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD011567.pub2-BIB0084|cit84","first-page":"119","article-title":"Selective monoamine uptake inhibitors and a serotonin antagonist in the treatment of panic disorder","volume":"25","author":"Westenberg","year":"1989","journal-title":"Psychopharmacology Bulletin"},{"issue":"6","key":"10.1002\/14651858.CD011567.pub2-BIB0085|cit85","first-page":"410","article-title":"Paroxetine versus clomipramine for the treatment of panic disorders: a double-blind randomised study","volume":"14","author":"Zhang","year":"2000","journal-title":"Chinese Mental Health Journal"},{"issue":"1","key":"10.1002\/14651858.CD011567.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/00004714-199402000-00011","article-title":"The use of the reversible monoamine oxidase-A inhibitor brofaromine in social phobia complicated by panic disorder with or without agoraphobia","volume":"14","author":"Bakish","year":"1994","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011567.pub2-BIB0087|cit87","first-page":"S52","article-title":"Depression comorbid with panic disorder or other anxiety disorders: a 16-week multicentre randomised parallel-group trial of moclobemide versus paroxetine","volume":"10","author":"Baldini Rossi","year":"2000","journal-title":"European Neuropsychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD011567.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/0278-5846(91)90049-7","article-title":"The changes of thyroid hormone during pharmacological treatment of panic disorder patients","volume":"15","author":"Balon","year":"1991","journal-title":"Progress in Neuropsychopharmacology and Biological Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD011567.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/070674379303800106","article-title":"Changes in appetite and weight during the pharmacological treatment of patients with panic disorder","volume":"38","author":"Balon","year":"1993","journal-title":"Canadian Journal of Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD011567.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1176\/ajp.147.11.1575a","article-title":"Initial reaction and subsequent response to antidepressants in panic patients","volume":"147","author":"Bystritsky","year":"1990","journal-title":"American Journal of Psychiatry"},{"issue":"12","key":"10.1002\/14651858.CD011567.pub2-BIB0091|cit91","first-page":"580","article-title":"Drug treatment of panic disorder: the comparative efficacy of imipramine, alprazolam, and trazodone","volume":"47","author":"Charney","year":"1986","journal-title":"Journal of Clinical Psychiatry"},{"issue":"11 pt 2","key":"10.1002\/14651858.CD011567.pub2-BIB0092|cit92","first-page":"4","article-title":"Anxiety: differential diagnosis and treatment from a biologic perspective","volume":"42","author":"Davis","year":"1981","journal-title":"Journal of Clinical Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD011567.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1055\/s-2007-1014613","article-title":"A comparative study of suriclone, lorazepam and placebo in anxiety disorder","volume":"22","author":"Jonghe","year":"1989","journal-title":"Pharmacopsychiatry"},{"issue":"6","key":"10.1002\/14651858.CD011567.pub2-BIB0094|cit94","first-page":"397","article-title":"Effectiveness treatment for panic and agoraphobia in comparison between drug and specialized psychological treatment","volume":"41","author":"Dell'Erba","year":"2006","journal-title":"Rivista di Psichiatria"},{"issue":"1","key":"10.1002\/14651858.CD011567.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/00004850-198701000-00002","article-title":"Effect of serotonin uptake inhibitors in anxiety disorders; a double-blind comparison of clomipramine and fluvoxamine","volume":"2","author":"Boer","year":"1987","journal-title":"International Clinical Psychopharmacology"},{"issue":"9","key":"10.1002\/14651858.CD011567.pub2-BIB0096|cit96","first-page":"458","article-title":"Effect of alprazolam and diazepam on anxiety and panic attacks in panic disorder: a controlled study","volume":"47","author":"Dunner","year":"1986","journal-title":"Journal of Clinical Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD011567.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/BF01182877","article-title":"Treatment of negative crises (panic attacks)","volume":"22","author":"Dyukova","year":"1992","journal-title":"Neuroscience and Behavioral Physiology"},{"issue":"1","key":"10.1002\/14651858.CD011567.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1600-0447.1986.tb02666.x","article-title":"Effect of a selective serotonin uptake inhibitor in agoraphobia with panic attacks. A double-blind comparison of zimeldine, imipramine and placebo","volume":"73","author":"Evans","year":"1986","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"1 pt B","key":"10.1002\/14651858.CD011567.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/00002826-199202001-00182","article-title":"Clomipramine and lofepramine in DSM III-R panic disorder: a placebo controlled trial","volume":"15","author":"Fahy","year":"1992","journal-title":"Clinical Neuropharmacology"},{"issue":"1","key":"10.1002\/14651858.CD011567.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0165-0327(92)90094-M","article-title":"The Galway Study of Panic Disorder. I: Clomipramine and lofepramine in DSM III-R panic disorder: a placebo controlled trial","volume":"25","author":"Fahy","year":"1992","journal-title":"Journal of Affective Disorders"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0101|cit101","first-page":"101","article-title":"Clomipramine and diazepam plasma levels in panic disorder and agoraphobia. Preliminary findings","volume":"27","author":"Franulic","year":"1989","journal-title":"Revista Chilena de Neuro-Psiquiatria"},{"issue":"10","key":"10.1002\/14651858.CD011567.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1002\/da.20532","article-title":"Evidence-based guidelines for interpretation of the Panic Disorder Severity Scale","volume":"26","author":"Furukawa","year":"2009","journal-title":"Depression and Anxiety"},{"issue":"6","key":"10.1002\/14651858.CD011567.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0010-440X(98)90043-8","article-title":"Pretreatment patient factors predicting attrition from a multicenter randomized controlled treatment study for panic disorder","volume":"39","author":"Grilo","year":"1998","journal-title":"Comprehensive Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD011567.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0165-0327(93)90074-T","article-title":"Influence of depression on the treatment of panic disorder with imipramine, alprazolam and placebo","volume":"28","author":"Keller","year":"1993","journal-title":"Journal of Affective Disorders"},{"issue":"2","key":"10.1002\/14651858.CD011567.pub2-BIB0105|cit105","first-page":"163","article-title":"Effect size as a measure of symptom-specific drug change in clinical trials","volume":"29","author":"Leon","year":"1993","journal-title":"Psychopharmacology Bulletin."},{"issue":"4","key":"10.1002\/14651858.CD011567.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0165-0327(94)90134-1","article-title":"Anxiety psychopathology predictive of outcome in patients with panic disorder and depression treated with imipramine, alprazolam and placebo","volume":"30","author":"Pollack","year":"1994","journal-title":"Journal of Affective Disorders"},{"issue":"2","key":"10.1002\/14651858.CD011567.pub2-BIB0107|cit107","first-page":"273","article-title":"Pattern of placebo response in panic disorder","volume":"31","author":"Shear","year":"1995","journal-title":"Psychopharmacology Bulletin"},{"issue":"4","key":"10.1002\/14651858.CD011567.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1159\/000118574","article-title":"Long-term effects of alprazolam and imipramine on cerebrospinal fluid monoamine metabolites and neuropeptides in panic disorder","volume":"21","author":"Lepola","year":"1989","journal-title":"Neuropsychobiology"},{"issue":"3","key":"10.1002\/14651858.CD011567.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/10401230309085686","article-title":"Imipramine vs. sertraline in panic disorder: 24-week treatment completers","volume":"15","author":"Mavissakalian","year":"2003","journal-title":"Annals of Clinical Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD011567.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.4088\/JCP.v68n0710","article-title":"Cost-efficacy of individual and combined treatments for panic disorder","volume":"68","author":"McHugh","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1 pt B","key":"10.1002\/14651858.CD011567.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/00002826-199202001-01046","article-title":"Combination of alprazolam, antidepressive drugs and cognitive behavior therapy in the treatment of panic disorder","volume":"15","author":"Miretzky","year":"1992","journal-title":"Clinical Neuropharmacology"},{"issue":"5","key":"10.1002\/14651858.CD011567.pub2-BIB0112|cit112","first-page":"679","article-title":"Ketazolam in the treatment of anxiety: a standard and placebo controlled study","volume":"31","author":"Nair","year":"1982","journal-title":"Current Therapeutic Research, Clinical & Experimental"},{"issue":"1","key":"10.1002\/14651858.CD011567.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/JCP.0b013e31823fe4bd","article-title":"A randomized, naturalistic, parallel-group study for the long-term treatment of panic disorder with clonazepam or paroxetine","volume":"32","author":"Nardi","year":"2012","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD011567.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/JCP.0b013e318210b4ee","article-title":"Randomized, open naturalistic, acute treatment of panic disorder with clonazepam or paroxetine","volume":"31","author":"Nardi","year":"2011","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD011567.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1590\/S0100-879X2011000400015","article-title":"Psychopharmacotherapy of panic disorder: 8-week randomized trial with clonazepam and paroxetine","volume":"44","author":"Nardi","year":"2011","journal-title":"Brazilian Journal of Medical and Biological Research"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0116|cit116","unstructured":"Ipca Laboratories Ltd Comparative Evaluation of Efficacy and Safety of Clonazepam-CR and Conventional Clonazepam in Patients with Panic Disorder http:\/\/www.ctri.nic.in"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0117|cit117","unstructured":"Pfizer A double-blind, placebo-controlled, parallel-group comparison of venlafaxine extended-release capsules and paroxetine in outpatients with panic disorder http:\/\/clinicaltrials.gov\/show\/NCT00044772 2002"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0118|cit118","unstructured":"Pfizer Pilot study of venlafaxine extended release (XR) in the treatment of panic disorder (PD) in comparison to paroxetine http:\/\/clinicaltrials.gov\/show\/NCT00195598 2005"},{"issue":"2","key":"10.1002\/14651858.CD011567.pub2-BIB0119|cit119","first-page":"99","article-title":"Clinical results on the use of lorazepam to treat panic attacks","volume":"24","author":"Pohl","year":"1989","journal-title":"Rivista di Psichiatria"},{"issue":"2","key":"10.1002\/14651858.CD011567.pub2-BIB0120|cit120","first-page":"224","article-title":"Lorazepam vs. alprazolam in the treatment of panic disorder","volume":"24","author":"Schweizer","year":"1988","journal-title":"Psychopharmacol Bulletin"},{"issue":"2","key":"10.1002\/14651858.CD011567.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1055\/s-2007-1014489","article-title":"Lorazepam vs. alprazolam in the treatment of panic disorder","volume":"23","author":"Schweizer","year":"1990","journal-title":"Pharmacopsychiatry"},{"issue":"3","key":"10.1002\/14651858.CD011567.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1177\/02698811030173009","article-title":"Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder","volume":"17","author":"Pollack","year":"2003","journal-title":"Journal of Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD011567.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/00004714-198902000-00004","article-title":"Double-blind comparison of alprazolam and adinazolam for panic and phobic disorders","volume":"9","author":"Pyke","year":"1989","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0167-4943(02)00111-5","article-title":"Therapy of panic attacks in the elderly","volume":"8","author":"Raffaele","year":"2002","journal-title":"Archives of Gerontology and Geriatrics. Supplement"},{"issue":"3","key":"10.1002\/14651858.CD011567.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/sj.npp.1300373","article-title":"Independent evaluator knowledge of treatment in a multicenter comparative treatment study of panic disorder","volume":"29","author":"Roll","year":"2004","journal-title":"Neuropsychopharmacology"},{"issue":"9","key":"10.1002\/14651858.CD011567.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1001\/archpsyc.58.9.869","article-title":"A randomized effectiveness trial of collaborative care for patients with panic disorder in primary care","volume":"58","author":"Roy-Byrne","year":"2001","journal-title":"Archives of General Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD011567.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/archpsyc.1980.01780140053006","article-title":"Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms","volume":"37","author":"Sheehan","year":"1980","journal-title":"Archives of General Psychiatry"},{"issue":"8-9","key":"10.1002\/14651858.CD011567.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/0006-3223(86)90242-8","article-title":"Immunological response to stress in agoraphobia and panic attacks","volume":"21","author":"Surman","year":"1986","journal-title":"Biological Psychiatry"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD011567.pub2-BIB0129|cit129","first-page":"14","article-title":"Clonazepam and imipramine in the treatment of panic attacks: a double-blind comparison of efficacy and side effects","volume":"51","author":"Svebak","year":"1990","journal-title":"Journal of Clinical Psychiatry"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011567.pub2-BIB0130|cit130","first-page":"S295","article-title":"Clinical evaluation of paroxetine HCl, a selective serotonin reuptake inhibitor, in the treatment of panic disorder: Phase III double-blind, parallel group study","volume":"28","author":"Tsutsui","year":"2000","journal-title":"Japanese Pharmacology & Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD011567.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1017\/S0033291700017736","article-title":"The Nottingham Study of Neurotic Disorder: relationship between personality status and symptoms","volume":"20","author":"Tyrer","year":"1990","journal-title":"Psychological Medicine"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1192\/bjp.162.2.219","article-title":"The Nottingham study of neurotic disorder. Effect of personality status on response to drug treatment, cognitive therapy and self-help over two years","volume":"162","author":"Tyrer","year":"1993","journal-title":"British Journal of Psychiatry"},{"issue":"8605","key":"10.1002\/14651858.CD011567.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(88)92535-4","article-title":"The Nottingham study of neurotic disorder: comparison of drug and psychological treatments","volume":"2","author":"Tyrer","year":"1988","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD011567.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1600-0447.2008.01157.x","article-title":"Is a combined therapy more effective than either CBT or SSRI alone? Results of a multicenter trial on panic disorder with or without agoraphobia","volume":"117","author":"Apeldoorn","year":"2008","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"3","key":"10.1002\/14651858.CD011567.pub2-BIB0135|cit135","first-page":"133","article-title":"The control study of mirtazapine in treating patients with panic disorder","volume":"17","author":"Yang","year":"2005","journal-title":"Medical Journal of Chinese People Health"},{"issue":"2","key":"10.1002\/14651858.CD011567.pub2-BIB0136|cit136","first-page":"186","article-title":"Effect of citalopram in the treatment of panic disorder","volume":"19","author":"Yang","year":"2006","journal-title":"Shandong Archives of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD011567.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000118801","article-title":"Imipramine-induced jitteriness and decreased serum iron levels","volume":"25","author":"Yeragani","year":"1992","journal-title":"Neuropsychobiology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011567.pub2-BIB0138|cit138","first-page":"10","article-title":"The effect of nefazodone on comorbid anxiety symptoms associated with depression: experience in family practice and psychiatric outpatient settings","volume":"57","author":"Zajecka","year":"1996","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD011567.pub2-BIB0139|cit139","first-page":"44","article-title":"Comparative study of citalopram and imipramine in the treatment of panic disorder","volume":"28","author":"Minutentag","year":"2001","journal-title":"Revista de Psiquiatria Clinica"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1001\/jama.290.7.921","article-title":"Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?","volume":"290","author":"Als-Nielsen","year":"2003","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness for summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0142|cit142","volume-title":"Diagnostic and Statistical Manual of Mental Disorders (DSM-III)","author":"American Psychiatric Association","year":"1980"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0143|cit143","volume-title":"Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)","author":"American Psychiatric Association","year":"1994"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0144|cit144","unstructured":"American Psychiatric Association Practice Guideline for the Treatment of Patients With Panic Disorder. Second Edition. 2009 Available from http:\/\/psychiatryonline.org\/pb\/assets\/raw\/sitewide\/practice_guidelines\/guidelines\/panicdisorder.pdf"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0145|cit145","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders (DSM-5)","author":"American Psychiatric Association","year":"2013"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0146|cit146","unstructured":"American Psychiatric Association Highlights of Changes from DSM-IV-TR to DSM-5. 2013 Available from http:\/\/www.dsm5.org\/Documents\/changes%20from%20dsm-iv-tr%20to%20dsm-5.pdf"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1034\/j.1600-0447.2002.02255.x","article-title":"SSRIs vs. TCAs in the treatment of panic disorder: a meta-analysis","volume":"106","author":"Bakker","year":"2002","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD011567.pub2-BIB0148|cit148","first-page":"47","article-title":"Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety","volume":"59","author":"Ballenger","year":"1998","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.4088\/JCP.v67n0914","article-title":"What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder?","volume":"67","author":"Bandelow","year":"2006","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/0269881105059253","article-title":"Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology","volume":"19","author":"Baldwin","year":"2005","journal-title":"Journal of Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD011567.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1017\/S1461145711000800","article-title":"Evidence-based pharmacotherapy of panic disorder: an update","volume":"15","author":"Batelaan","year":"2012","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0152|cit152","first-page":"477","article-title":"Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials","volume":"170","author":"Bhandari","year":"2004","journal-title":"Canadian Medical Association Journal"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s001270050098","article-title":"Prevalence of psychiatric disorder in the general population: results of The Netherlands Mental Health Survey and Incidence Study (NEMESIS)","volume":"33","author":"Bijl","year":"1998","journal-title":"Social Psychiatry and Psychiatric Epidemiology"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0154|cit154","first-page":"405","article-title":"The problem of therapeutic efficacy indices. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/00002826-199310000-00002","article-title":"Neurobiological mechanisms involved in antidepressant therapies","volume":"16","author":"Briley","year":"1993","journal-title":"Clinical Neuropharmacology"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1176\/appi.ajp.160.8.1432","article-title":"Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia?","volume":"160","author":"Bruce","year":"2003","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1345\/aph.1D267","article-title":"Industry sponsorship and authorship of clinical trials over 20 years","volume":"38","author":"Buchkowsky","year":"2004","journal-title":"Annals of Pharmacotherapy"},{"issue":"7","key":"10.1002\/14651858.CD011567.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jclinepi.2005.11.010","article-title":"Single data extraction generated more errors than double data extraction in systematic reviews","volume":"59","author":"Buscemi","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/archpsyc.64.7.793","article-title":"Reduced gamma-aminobutyric acid(A)-benzodiazepine binding sites in insular cortex of individuals with panic disorder","volume":"64","author":"Cameron","year":"2007","journal-title":"Archives of General Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD011567.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1002\/sim.1188","article-title":"Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes","volume":"21","author":"Deeks","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1176\/ajp.151.3.413","article-title":"Panic and panic disorder in the United States","volume":"151","author":"Eaton","year":"1994","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/ije\/31.1.72","article-title":"Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses","volume":"31","author":"Furukawa","year":"2002","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00004850-200501000-00010","article-title":"Imputing response rates from means and standard deviations in meta-analysis","volume":"20","author":"Furukawa","year":"2005","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2000","journal-title":"Journal of Clinical Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD011567.pub2-BIB0166|cit166","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004364.pub2","article-title":"Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia","author":"Furukawa","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1176\/ajp.152.10.1438","article-title":"DSM-IV and the disappearance of agoraphobia without a history of panic disorder: new data on a controversial diagnosis","volume":"152","author":"Goisman","year":"1995","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1176\/appi.ajp.157.4.493","article-title":"Neuroanatomical hypothesis of panic disorder, revised","volume":"157","author":"Gorman","year":"2000","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"363","DOI":"10.4088\/JCP.v67n0305","article-title":"The epidemiology of DSM-IV panic disorder and agoraphobia in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions","volume":"67","author":"Grant","year":"2006","journal-title":"Journal of Clinical Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD011567.pub2-BIB0170|cit170","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010677","article-title":"Benzodiazepines versus placebo for panic disorder in adults","author":"Guaiana","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD011567.pub2-BIB0171|cit171","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010676","article-title":"Antidepressants versus placebo for panic disorder in adults","author":"Guaiana","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0172|cit172","doi-asserted-by":"crossref","unstructured":"Guaiana G Barbui C Caldwell D Davies SJC Furukawa T Imai H Antidepressants, benzodiazepines and azapirones for panic disorder in adults: a network meta-analysis Cochrane Database of Systematic Reviews 2014 (Data on file)","DOI":"10.1002\/14651858.CD010828"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0173|cit173","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1001\/archpsyc.63.4.415","article-title":"The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication","volume":"63","author":"Kessler","year":"2006","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1192\/bjp.bp.107.039966","article-title":"Prevalence of common mental disorders in general practice attendees across Europe","volume":"192","author":"King","year":"2008","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/BF02193476","article-title":"Delineation of two drug-responsive anxiety syndromes","volume":"5","author":"Klein","year":"1964","journal-title":"Psychopharmacologia"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/bmj.326.7400.1167","article-title":"Pharmaceutical industry sponsorship and research outcome and quality: systematic review","volume":"326","author":"Lexchin","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/archpsyc.55.8.715","article-title":"Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study","volume":"55","author":"Malizia","year":"1998","journal-title":"Archives of General Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD011567.pub2-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Medicine"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1192\/bjp.bp.107.041186","article-title":"Serotonin 5-HT1A receptor binding in people with panic disorder: positron emission tomography study","volume":"1993","author":"Nash","year":"2008","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0181|cit181","unstructured":"National Institute for Health and Care Excellence Generalised anxiety disorder and panic disorder (with or without agoraphobia) in adults: Management in primary, secondary and community care. NICE guidelines [CG113]. Published date: January 2011 Available from http:\/\/www.nice.org.uk\/guidance\/cg113\/chapter\/guidance"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1159\/000353198","article-title":"Efficacy and tolerability of benzodiazepines versus antidepressants in anxiety disorders: a systematic review and meta-analysis","volume":"82","author":"Offidani","year":"2013","journal-title":"Psychotherapy and Psychosomatics"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1176\/appi.ajp.158.12.1989","article-title":"An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder","volume":"158","author":"Otto","year":"2000","journal-title":"American Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD011567.pub2-BIB0184|cit184","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011004.pub2","article-title":"Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis","author":"Pompoli","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cpr.2009.08.011","article-title":"Psychological treatment of panic disorder with or without agoraphobia: a meta-analysis","volume":"30","author":"S\u00e1nchez-Meca","year":"2010","journal-title":"Clinical Psychology Review"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0186|cit186","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780195369250.001.0001","volume-title":"Anxiety Disorders in Adults: A Clinical Guide","author":"Starcevic","year":"2009"},{"issue":"11","key":"10.1002\/14651858.CD011567.pub2-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1586\/14737175.2014.963057","article-title":"The reappraisal of benzodiazepines in the treatment of anxiety and related disorders","volume":"14","author":"Starcevic","year":"2014","journal-title":"Expert Review of Neurotherapeutics"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/7854_2009_35","article-title":"Pharmacologic treatment of panic disorder","volume":"2","author":"Stein","year":"2010","journal-title":"Current Topics in Behavioral Neurosciences"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011567.pub2-BIB0189|cit189","first-page":"13","article-title":"Antidepressants in panic disorder","volume":"14","author":"Wade","year":"1999","journal-title":"International Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD011567.pub2-BIB0190|cit190","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005335.pub2","article-title":"Combined psychotherapy plus benzodiazepines for panic disorder","author":"Watanabe","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0191|cit191","unstructured":"World Health Organization Introduction to drug utilization research. WHO International Working Group for Drug Statistics Methodology; WHO Collaborating Centre for Drug Statistics Methodology; WHO Collaborating Centre for Drug Utilization Research and Clinical Pharmacological Services. 2003 Available from http:\/\/www.who.int\/medicines\/areas\/quality_safety\/safety_efficacy\/utilization\/en\/"},{"key":"10.1002\/14651858.CD011567.pub2-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1017\/S0033291700029986","article-title":"Meta-analysis of double-blind placebo-controlled trials of antidepressants and benzodiazepines for patients with panic disorders","volume":"21","author":"Wilkinson","year":"1991","journal-title":"Psychological Medicine"},{"issue":"Issue 3","key":"10.1002\/14651858.CD011567.pub2-BIB0193|cit193","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011567","article-title":"Antidepressants and benzodiazepines for panic disorder in adults","author":"Guaiana","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD011567.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T03:38:49Z","timestamp":1717731529000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD011567.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Common Mental Disorders Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,9,12]]},"references-count":193,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2016,9]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011567.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,12]]}}}